医学临床研究
   Apr. 5, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (8): 1174-1177    DOI: 10.3969/j.issn.1671-7171.2022.08.015
Original Articles Current Issue | Archive | Adv Search |
Expression and Clinical Significance of Semaphorin 3A and CXCL12 in Vitreous Humor and Serum of Patients with Diabetic Retinopathy
ZHAO Ming, MA Wen-ting
Department of Vitreoretinal Surgery,Xianyang First People's Hospital,Xianyang Shaanxi 712000
Download: PDF (1260 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To investigate the expression and clinical significance of semaphorin 3A (Sema 3A) and CXC chemokine ligand 12 (CXCL12) in vitreous humor and serum of patients with diabetic retinopathy (DR). 【Methods】A total of 113 DR patients who were diagnosed and treated in our hospital from July 2019 to July 2021 were collected as the research objects. The DR patients were divided into proliferative diabetic retinopathy (PDR) group (n=44) and non-proliferative diabetic retinopathy (NPDR) group (n=69) according to the international clinical classification of DR. In addition,52 healthy volunteers who underwent physical examination in our hospital were as the control group. The general information and biochemical indicators of the research subjects were collected,the levels of Sema 3A and CXCL12 in serum and vitreous humor were detected by enzyme-linked immunosorbent assay; the influencing factors of DR were analyzed by logistic regression; and the clinical value of Sema 3A and CXCL12 levels in predicting the occurrence of PDR was analyzed by receiver operating characteristic (ROC) curve. 【Results】The levels of Sema 3A and CXCL12 in the vitreous humor and serum of the patients in the PDR group were higher than those in the NPDR group (P<0.05). The levels of Sema 3A and CXCL12 in the serum of the patients in the PDR and NPDR groups were higher than those in the control group (P<0.05). Levels of HbA1c,TC,TG,LDL-C,HDL-C,and FPG in the PDR group and NPDR group were higher than those in the control group,and these indicators in the PDR group were higher than that in the NPDR group,with statistical significance (P<0.05). the expression of Sema 3A and CXCL12 in serum of DR patients was positively correlated (r=0.664,P<0.05),and the expression of Sema 3A and CXCL12 in vitreous humor was positively correlated (r=0.457,P<0.05). Logistic regression analysis showed that Sema 3A,CXCL12,FPG,HbA1c,HDL-C,TC,TG and LDL-C were all risk factors for DR (P<0.05). ROC curve showed that the areas under the curve (AUC) of serum Sema 3A and CXCL12 levels for predicting PDR were 0.951 (95%CI:0.906-0.979) and 0.953 (95%CI:0.909-0.980),respectively; and the corresponding sensitivities were 93.18 % and 95.45%,respectively,the specificities were 91.74% and 82.64%,respectively. The combined predictive AUC of serum Sema 3A combined with CXCL12 levels was 0.981 (95%CI:0.947-0.996),with a sensitivity of 95.45% and a specificity of 92.56%. 【Conclusion】The levels of Sema 3A and CXCL12 in serum and vitreous humor of patients with PDR are up-regulated,which are closely related to the occurrence and development of DR,and can be used as potential indicators to evaluate the occurrence of PDR.
Key wordsDiabetic Retinopathy      Vitreous Body      Semaphorin-3A/BL      Chemokine CXCL12/BL     
Received: 08 March 2022     
PACS:  R587.26  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
ZHAO Ming
MA Wen-ting
Cite this article:   
ZHAO Ming,MA Wen-ting. Expression and Clinical Significance of Semaphorin 3A and CXCL12 in Vitreous Humor and Serum of Patients with Diabetic Retinopathy[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1174-1177.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.08.015     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I8/1174
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech